Kadmon Holdings (KDMN) PT Raised to $9 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease
May 21, 2020 7:26 AM EDTORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, Respectively
Kadmon Participating in FDA's Real-Time Oncology Review Pilot Program
Conference Call Today at 8:30 a.m. Eastern Time
NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Kadmon Holdings, Inc. (NYSE:... More
